🎗️ Cervical cancer FIGO 2018 staging
Assign the FIGO 2018 cervical cancer stage from local extent, nodal status, adjacent-organ and distant spread, with a stage-specific management direction. Instant, browser-side.
Clinical takeaway
A key 2018 change: any nodal metastasis (any size, imaging r or pathology p) upstages to IIIC, recorded with an r/p notation.
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Staging and first-line management direction for cervical cancer using the FIGO 2018 system (which incorporates imaging and pathology).
How it works
Highest level of involvement defines the stage: IA microscopic (≤ 3 / > 3–5 mm) → IB by size (≤ 2 / 2–4 / > 4 cm); II beyond uterus (IIA vagina / IIB parametria); III lower vagina (IIIA), pelvic wall/hydronephrosis (IIIB), pelvic nodes (IIIC1) / para-aortic (IIIC2); IVA mucosa/beyond pelvis, IVB distant.
Key points
- A key 2018 change: any nodal metastasis (any size, imaging r or pathology p) upstages to IIIC, recorded with an r/p notation.
- IB is subdivided by size (≤ 2 / > 2–4 / > 4 cm) into IB1/IB2/IB3 — a 2018 refinement over the older IB1/IB2 split.
- Early disease (≤ IIA1) is mainly surgical; IB3 and locally advanced disease are mainly concurrent platinum chemoradiation + brachytherapy.
- Fertility-sparing options exist for selected IA–IB1 disease.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Local tumor extent | IA1 — stromal invasion ≤ 3 mm (microscopic) |
|---|---|
| Nodal metastasis (imaging r or pathology p) | None |
| Bladder/rectal mucosa or beyond true pelvis | No |
| Distant metastases | No |
→FIGO stageIA1
- FIGO 2018：IA1 (stromal invasion ≤ 3 mm)
- Management direction：Conization or extrafascial hysterectomy; fertility preservation possible if LVSI-negative and margins clear; LVSI+ → consider pelvic nodal assessment
- Note：FIGO 2018 incorporates imaging (r) and pathology (p); any positive node → IIIC; stage IA requires microscopic assessment of the entire lesion
| Local tumor extent | IIIB — pelvic wall / hydronephrosis |
|---|---|
| Nodal metastasis (imaging r or pathology p) | Para-aortic nodes (→ IIIC2) |
| Bladder/rectal mucosa or beyond true pelvis | Yes (→ IVA) |
| Distant metastases | Yes (→ IVB) |
→FIGO stageIVB
- FIGO 2018：IVB (distant metastases)
- Management direction：Systemic therapy (platinum ± bevacizumab ± checkpoint inhibitor if PD-L1+) ± palliative radiation
- Note：FIGO 2018 incorporates imaging (r) and pathology (p); any positive node → IIIC; stage IA requires microscopic assessment of the entire lesion
Frequently asked questions
- What is Cervical cancer FIGO 2018 staging?
- Assign the FIGO 2018 cervical cancer stage from local extent, nodal status, adjacent-organ and distant spread, with a stage-specific management direction. Instant, browser-side.
- How is Cervical cancer FIGO 2018 staging calculated? What is the core formula?
- Highest level of involvement defines the stage: IA microscopic (≤ 3 / > 3–5 mm) → IB by size (≤ 2 / 2–4 / > 4 cm); II beyond uterus (IIA vagina / IIB parametria); III lower vagina (IIIA), pelvic wall/hydronephrosis (IIIB), pelvic nodes (IIIC1) / para-aortic (IIIC2); IVA mucosa/beyond pelvis, IVB distant.
- When is Cervical cancer FIGO 2018 staging used?
- Staging and first-line management direction for cervical cancer using the FIGO 2018 system (which incorporates imaging and pathology).
- What are the key clinical points for Cervical cancer FIGO 2018 staging?
- A key 2018 change: any nodal metastasis (any size, imaging r or pathology p) upstages to IIIC, recorded with an r/p notation. IB is subdivided by size (≤ 2 / > 2–4 / > 4 cm) into IB1/IB2/IB3 — a 2018 refinement over the older IB1/IB2 split. Early disease (≤ IIA1) is mainly surgical; IB3 and locally advanced disease are mainly concurrent platinum chemoradiation + brachytherapy. Fertility-sparing options exist for selected IA–IB1 disease.
- What are the limits and cautions when using Cervical cancer FIGO 2018 staging?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Cervical cancer FIGO 2018 staging calculated in practice? Can you show a worked example?
- Inputs: Local tumor extent IA1 — stromal invasion ≤ 3 mm (microscopic), Nodal metastasis (imaging r or pathology p) None, Bladder/rectal mucosa or beyond true pelvis No, Distant metastases No → Result: FIGO stage IA1（FIGO 2018: IA1 (stromal invasion ≤ 3 mm), Management direction: Conization or extrafascial hysterectomy; fertility preservation possible if LVSI-negative and margins clear; LVSI+ → consider pelvic nodal assessment, Note: FIGO 2018 incorporates imaging (r) and pathology (p); any positive node → IIIC; stage IA requires microscopic assessment of the entire lesion） Inputs: Local tumor extent IIIB — pelvic wall / hydronephrosis, Nodal metastasis (imaging r or pathology p) Para-aortic nodes (→ IIIC2), Bladder/rectal mucosa or beyond true pelvis Yes (→ IVA), Distant metastases Yes (→ IVB) → Result: FIGO stage IVB（FIGO 2018: IVB (distant metastases), Management direction: Systemic therapy (platinum ± bevacizumab ± checkpoint inhibitor if PD-L1+) ± palliative radiation, Note: FIGO 2018 incorporates imaging (r) and pathology (p); any positive node → IIIC; stage IA requires microscopic assessment of the entire lesion）